Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5046539 | 0.85 | HTT (0.45) | TAS2R14LMNAALDH1A1HTTMRGPRX4 | |
| SCHEMBL5046905 | 0.84 | TAS2R14 (0.50) | TAS2R14MRGPRX4 | |
| SCHEMBL2769588 | 0.83 | TAS2R14 (0.39) | TAS2R14MRGPRX4 | |
| SCHEMBL5047973 | 0.83 | LMNA (0.46) | TAS2R14LMNAMAPTHTT | |
| SCHEMBL5727230 | 0.83 | TAS2R14 (0.39) | TAS2R14ALDH1A1MRGPRX4 | |
| SCHEMBL5726407 | 0.83 | TAS2R14 (0.39) | TAS2R14MRGPRX4 | |
| SCHEMBL5726420 | 0.83 | TAS2R14 (0.41) | TAS2R14MRGPRX4 | |
| SCHEMBL5043363 | 0.83 | TAS2R14 (0.39) | TAS2R14LMNAHTT | |
| SCHEMBL5046412 | 0.82 | KDM4E (0.40) | TDP1TAS2R14LMNAALDH1A1MAPT | |
| SCHEMBL5046371 | 0.81 | TAS2R14 (0.43) | TAS2R14LMNAALDH1A1MAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442702-B2 | Treatment of bone disorders; carboxy derivatives | PFIZER INC. (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1021410-B1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER (US) | 2006-12-27 | — | — | EP | disclosed |
| US-20050203086-A1 | Methods of treatment using an EP2 selective receptor agonist | PFIZER INC. | 2005-09-15 | — | — | US | disclosed |
| US-20030078261-A1 | Prostaglandin agonists | CAMERON KIMBERLY O (US) | 2003-04-24 | — | — | US | disclosed |
| US-6498172-B1 | (3-(((4-TERT-BUTYL-BENZYL)-(PYRIDINE-3-SULFONYL)-AMINO)-METHYL) -PHENOXY)-ACETIC ACID OR SALT; TREATING SUCH AS OSTEOPOROSIS | PFIZER INC. | 2002-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203086-A1 | Methods of treatment using an EP2 selective receptor agonist | PTGER2, PTGES2, PTGFR | TDP1 2985/4885TAS2R14 518/4885LMNA 1786/4885 |
| US-20030078261-A1 | Prostaglandin agonists | PTGER1, PTGER4, PTGIR | TDP1 4306/4885TAS2R14 4081/4885LMNA 1317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.